Drug intelligence / Profile preview

TRT-448

Development stage: Phase 1
Lead developer: Transtech Pharma
Modality: Small Molecules
Administration: Oral

Overview

TRT-448 is an orally bioavailable small molecule inhibitor of Methyltransferase-like 3 (METTL3), developed by Trotana Therapeutics. METTL3 is the catalytic subunit of the N6-methyladenosine (m6A) methyltransferase complex, which plays a critical role in the epitranscriptomic regulation of RNA stability, splicing, and translation. By inhibiting METTL3, TRT-448 modulates the m6A RNA methylation landscape, which in turn dampens the expression of pro-inflammatory cytokines and mediators. The drug is currently in Phase 1 clinical development, with initial studies focused on safety and pharmacokinetics in healthy volunteers, intended for the treatment of various inflammatory diseases.

Targets

METTL3 (Methyltransferase-like protein 3)

Beyond the preview

Go deeper on TRT-448.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRT-448.

Explore the full profile